YTB323
Sponsors
Novartis Pharma AG, Novartis Pharma Services AG, Novartis Pharmaceuticals
Conditions
Acute lymphoblastic leukemiaAll patients who have been treated with Novartis or Penn CAR-T for any indicationChronic lymphocytic leukemia/Small lymphocytic lymphomaDifficult to treat rheumatoid arthritisDiffuse cutaneous systemic sclerosis (dcSSc)Diffuse large B-Cell lymphomaGeneralized Myasthenia GravisHigh-Risk large B-Cell lymphoma
Phase 1
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
Active, not recruitingNCT05798117
Start: 2023-02-28End: 2026-09-09Updated: 2026-03-23
An open-label, multi-center, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323 in participants with severe, refractory systemic lupus erythematosus (srSLE).
Active, not recruitingCTIS2023-510081-27-00
Start: 2023-02-28Target: 19Updated: 2025-09-26
Phase I/II, open label, multicenter study of rapcabtagene autoleucel in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Active, not recruitingCTIS2023-507062-34-00
Start: 2020-08-07Target: 142Updated: 2025-11-12
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
RecruitingNCT06704269
Start: 2025-04-22End: 2029-10-26Target: 15Updated: 2026-02-05
An open-label, multi-center, phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis
RecruitingCTIS2024-513589-20-00
Start: 2025-07-29Target: 3Updated: 2026-01-07
An open-label, multi-center, phase 1/2 study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with Relapsing Multiple Sclerosis with breakthrough disease activity during previous treatment with a highly efficacious therapy
RecruitingCTIS2024-512714-18-00
Start: 2025-11-11Target: 15Updated: 2026-01-19
An open-label, multi-center, phase I/II study to assess safety, disease progression, and cellular kinetics following YTB323 administration in participants with non-active Progressive Multiple Sclerosis (PMS)
Not yet recruitingCTIS2024-514006-31-00
Target: 18Updated: 2026-01-16
An open-label, multi-center, phase 1/2 study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in participants with difficult-to-treat rheumatoid arthritis and severe, refractory Sjogren's disease with organ involvement
RecruitingCTIS2024-514596-18-00
Start: 2025-06-20Target: 17Updated: 2025-10-17
Phase 2
A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN).
RecruitingCTIS2023-510150-17-00
Start: 2024-12-11Target: 69Updated: 2025-08-04
A Phase II, multi-part, five-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cutaneous systemic sclerosis
RecruitingCTIS2023-510380-34-00
Start: 2024-12-10Target: 80Updated: 2025-10-28
A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucelversus comparator in participants with severe refractory idiopathic inflammatory myopathies
RecruitingCTIS2024-514137-38-00
Start: 2025-02-04Target: 47Updated: 2025-11-10